{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:29:32Z","timestamp":1770748172791,"version":"3.49.0"},"reference-count":28,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Introduction: Prostate-specific antigen velocity (PSAV) is used to monitor men with clinical suspicion of prostate cancer (PCa), with a normal cut-off point of 0.3\u20130.5 ng\/mL\/year. The aim of the study is to establish the predictive capacity of PSAV (value and acceleration) and of the free PSA\/total PSA index or ratio. Method: Prospective multicentre observational study in 2035 men of over 47 years of age. Inclusion criteria: men who wished to be informed on the health of their prostate. Exclusion criteria: men with a previously diagnosed prostate condition. Groups: GA: (n = 518): men with serum PSA equal to or greater than 2.01 ng\/mL. GB: (n = 775): men with serum PSA greater than or equal to 0.78 ng\/mL and less than 2.01 ng\/mL. GC: (n = 742): men with serum PSA less than 0.78 ng\/mL. Variables: prostate-specific antigen (PSA); age; body mass index (BMI); PSA velocity (PSAV) (ng\/mL per year); free PSA\/total PSA index (iPSA); PSAV acceleration (increasing: positive, or decreasing: negative); prostate diagnosis (benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), or infectious and non-infectious prostatitis and prostatic adenocarcinoma (PCa)); de novo diagnoses of urinary tract diseases or conditions; concomitant treatments, diseases and conditions; final diagnosis of prostate health. Results: Mean age 62.35 years (SD 8.12), median 61 (47\u201394); age was lowest in GC. Mean BMI was 27.89 kg\/m2 (SD 3.96), median 27.58 (18.56\u201357.13); no differences between groups. Mean PSAV was 0.69, SD 2.16, median 0.13 (0.001\u201334.46); PSAV was lowest in GC. Mean iPSA was 27.39 u\/L (SD 14.25), median 24.29 (3.7\u2013115); iPSA was lowest in GA. PSAV had more positive acceleration in GA and more negative acceleration in GC. There were 1600 (78.62%) cases of normal prostate or BPH, 322 (15.82%) cases of PIN or non-infectious prostatitis, and 113 (5.55%) cases of PCa. There were more cases of BPH in GC and more cases of PIN or prostatitis and cancer in GA (p = 0.00001). De novo diagnoses: 15 cases of urinary incontinence (UI), 16 discomfort\/pain in LUT, 112 cases of voiding disorders, 12 urethral strictures, 19 hematuria, 51 cystitis, 3 pyelonephritis, 4 pelvic inflammatory disease; no differences were found between groups. In the multivariate analysis, PSAV and the direction of PSAV acceleration (positive or negative) were the variables which were correlated most strongly with prostate health. iPSA was associated with the presence of prostatitis, PCa, and BPH. Men in GA had more prostatitis, PCa, treatment with alpha blockers, and history of previous smoking. GB had more cases of BPH and more positive acceleration of PSAV. GC had more normal prostates, more BPH, more use of ranitidine, and more PSAV with negative acceleration. Conclusions: PSAV, direction of PSAV acceleration, and iPSA in PSA cut-off points of 0.78 ng\/mL and 2.01 ng\/mL in a priori healthy men over 47 predict the probability of benign or malignant pathology of the prostate.<\/jats:p>","DOI":"10.3390\/jcm9113400","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T08:59:28Z","timestamp":1603443568000},"page":"3400","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Association between Prostate-Specific Antigen Velocity (PSAV), Value and Acceleration, and of the Free PSA\/Total PSA Index or Ratio, with Prostate Conditions"],"prefix":"10.3390","volume":"9","author":[{"given":"Mar\u00eda-Carmen","family":"Flores-Fraile","sequence":"first","affiliation":[{"name":"Department of Surgery, University of Salamanca, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8566-6033","authenticated-orcid":false,"given":"B\u00e1rbara Yolanda","family":"Padilla-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Section of Urology, Departamento de Cirug\u00eda, Universidad de La Laguna, La Laguna, 38071 Tenerife, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2797-3262","authenticated-orcid":false,"given":"Sebasti\u00e1n","family":"Valverde-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Salamanca, 37007 Salamanca, Spain"},{"name":"Multidisciplinary Renal Research Group of the Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Department of Urology of University Hospital of Avila, 05004 \u00c1vila, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1046-0118","authenticated-orcid":false,"given":"Magaly","family":"Marquez-Sanchez","sequence":"additional","affiliation":[{"name":"Multidisciplinary Renal Research Group of the Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda-Bego\u00f1a","family":"Garc\u00eda-Cenador","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Salamanca, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1208-3408","authenticated-orcid":false,"given":"Mar\u00eda-Fernanda","family":"Lorenzo-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Salamanca, 37007 Salamanca, Spain"},{"name":"Multidisciplinary Renal Research Group of the Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Department of Urology of University Hospital of Salamanca, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1338-0551","authenticated-orcid":false,"given":"Javier","family":"Flores-Fraile","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Salamanca, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"key":"ref_1","first-page":"637","article-title":"Tumor de Pr\u00f3stata","volume":"Volume 1","year":"2013","journal-title":"Nefrourolog\u00eda"},{"key":"ref_2","unstructured":"Lorenzo-Gomez, M.-F., and Mac\u00edas-N\u00fa\u00f1ez, J.-F. (2013). Hiperplasia benigna de Pr\u00f3stata. Nefrourolog\u00eda, Cervantes Internacional. [\u00a9 MF Lorenzo G\u00f3mez ed.]. Volume II - Secci\u00f3n Urolog\u00eda."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1056\/NEJM198710083171501","article-title":"Prostate specific antigen as aserum marker for adenocarcinoma of the prostate","volume":"317","author":"Stamey","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0022-5347(17)35233-3","article-title":"Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6630 men","volume":"151","author":"Catalona","year":"1994","journal-title":"J. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/(SICI)1097-0045(1996)7+<3::AID-PROS1>3.0.CO;2-T","article-title":"Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values","volume":"29","author":"Semjonow","year":"1996","journal-title":"Prostate"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level <or =4.0 ng per milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_8","first-page":"322","article-title":"[Some physico-chemical characteristics of \u201c-seminoprotein\u201d, an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VII]","volume":"25","author":"Hara","year":"1971","journal-title":"Nihon Hoigaku zasshi Jpn J. Leg. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0959-8049(01)00267-2","article-title":"Cancer burden in the year 2000. The global picture","volume":"37","author":"Parkin","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0090-4295(98)00205-2","article-title":"An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: Results on 4298 cases","volume":"52","author":"Carlson","year":"1998","journal-title":"Urology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/(SICI)1097-0142(19970101)79:1<104::AID-CNCR15>3.0.CO;2-8","article-title":"The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia","volume":"79","author":"Stephan","year":"1997","journal-title":"Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1001\/jama.279.19.1542","article-title":"Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial","volume":"279","author":"Catalona","year":"1998","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1097\/01.ju.0000095460.12999.43","article-title":"Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng\/ml","volume":"170","author":"Catalona","year":"2003","journal-title":"J. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0090-4295(02)02398-1","article-title":"Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng\/ml total psa range: Preliminary analysis","volume":"61","author":"Sokoll","year":"2003","journal-title":"Urology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.1992.03480160073037","article-title":"Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease","volume":"267","author":"Carter","year":"1992","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/1097-0142(19930315)71:6<2031::AID-CNCR2820710618>3.0.CO;2-Q","article-title":"Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume","volume":"71","author":"Schmid","year":"1993","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.juro.2008.01.099","article-title":"Re: Prostate specific antigen working group guidelines on prostate specific antigen doubling time","volume":"179","author":"Arlen","year":"2008","journal-title":"J. Urol."},{"key":"ref_18","first-page":"3323","article-title":"Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease","volume":"52","author":"Carter","year":"1992","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/pros.2990160105","article-title":"The prostate: An increasing medical problem","volume":"16","author":"Carter","year":"1990","journal-title":"Prostate"},{"key":"ref_20","first-page":"41","article-title":"Sujetos participantes en la investigaci\u00f3n. Garant\u00edas","volume":"Volume 1","year":"2015","journal-title":"Gu\u00eda de Buenas Pr\u00e1cticas en Investigaci\u00f3n"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"J. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.urolonc.2014.04.010","article-title":"PSA velocity: A systematic review of clinical applications","volume":"32","author":"Loughlin","year":"2014","journal-title":"Urologic Oncol."},{"key":"ref_23","unstructured":"San-Bartolom\u00e9-Guti\u00e9rrez, J. (2017). Estudio de Incidencia de C\u00e1ncer de Pr\u00f3stata en la Provincia de Salamanca, Universidad de Salamanca (Espa\u00f1a). Original Research."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.urology.2013.09.075","article-title":"A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer","volume":"83","author":"Vickers","year":"2014","journal-title":"Urology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJM199605303342204","article-title":"Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs","volume":"334","author":"Taha","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_26","first-page":"123","article-title":"Guia de pr\u00e1ctica cl\u00ednica para el diagn\u00f3stico y tratamiento de la hiperprolactinemia","volume":"82","year":"2014","journal-title":"Ginecol. Obstet. Mex."},{"key":"ref_27","first-page":"720","article-title":"Testosterona y ant\u00edgeno prost\u00e1tico espec\u00edfico en pacientes portadores de carcinoma prost\u00e1tico, provincia Holgu\u00edn, 2013\u20132015","volume":"21","year":"2017","journal-title":"Correo Cient. M\u00e9d."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0210-4806(03)73015-0","article-title":"Relaci\u00f3n entre niveles de tertosterona en suero y c\u00e1ncer prost\u00e1tico","volume":"27","author":"Rivera","year":"2003","journal-title":"Actas Urol. Esp."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/11\/3400\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:27:02Z","timestamp":1760178422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/11\/3400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["jcm9113400"],"URL":"https:\/\/doi.org\/10.3390\/jcm9113400","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,23]]}}}